Walder Wyss advised Nasdaq-listed CRISPR Therapeutics, as the Switzerland-based biopharmaceutical company issued a USD 600 million aggregate principal amount of convertible senior notes. The convertible senior notes were offered in a private offering to qualified institutional
Vaudoise Assurance Group, through its subsidiary Vaudoise Asset Management, has entered into an agreement to increase its stake and become the majority shareholder in Procimmo Group, a company listed on BX Swiss in which Vaudoise
Kellerhals Carrard Startup & VC Desk advised Vsquared Ventures and World Fund, in connection with their role as lead investors in Hyperscale Power’s EUR 5 million seed funding round. Headquartered in Zurich, Hyperscale specialises in
Swiss dermatology specialist Galderma issued EUR 500 million bonds due 2031 with a coupon of 3.375%. In connection with the operation, Advestra represented Galderma, while Walder Wyss advised the banking syndicate, consisting of Citigroup, ING, RBC Capital Markets
Bär & Karrer advised Airsol, part of SOL Group — an Italian spcialist in the production, research and marketing of technical and medical gases and homecare services sector — on its acquisition of VitalAire Switzerland from
Lenz & Staehelin, working alongside Milbank, advised Philippines-based infrastructure investor Prime Infrastructure in connection with its acquisition of SierraCol Energy, an independent oil and gas exploration and production company, from Nasdaq-listed investment firm Carlyle. The
Sulzer appointed Andrea Rüttimann (pictured) as deputy general counsel, head group legal & corporate secretary, effective 1 May 2026. In her new role, Rüttimann will lead the group legal team and oversee corporate secretary responsibilities,
Wenger Vieli advised institutional staking infrastructure provider Chorus One, and its shareholders, on all Swiss legal and tax aspects of the company’s sale to Bitwise Asset Management. Pursuant to the deal, Chorus One joins
Kellerhals Carrard advised Seprify on a CHF 12.25 million series A financing round. Headquartered in Marly, Seprify engineers cellulose at the micro- and nano-scale to create materials capable of replacing titanium dioxide (TiO₂). Una Terra Early
Advestra advised Sandoz, a generic and biosimilar medicines specialist with headquarters in Basel, on its CHF 550 million bonds issuance. The issuance comprises a CHF 275 million tranche with a six-year maturity and a 1.1875% coupon, and a
